

United States Patent and Trademark Office

010

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/669,099	09/22/2003	Stephen R. Gorfine	010692-004532US	1846	
20350 75	590 06/17/2005	EXAMINER			
TOWNSEND AND TOWNSEND AND CREW, LLP			TATE, CHRISTOPHER ROBIN		
TWO EMBARCADERO CENTER EIGHTH FLOOR		ART UNIT	PAPER NUMBER		
SAN FRANCIS	SCO, CA 94111-3834		1654		
				DATE MAILED: 06/17/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

U.S. Patent and Trademark Office PTOL-326 (Rev. 1-04) Office	e Action Summary	Part of Paper No./Mail Date 0605	ß			
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SE Paper No(s)/Mail Date	$^{\prime}$	nary (PTO-413) ail Date nal Patent Application (PTO-152)				
application from the International Bu * See the attached detailed Office action for a		eived.				
3. Copies of the certified copies of the						
2. Certified copies of the priority docum		cation No				
1. Certified copies of the priority docum	nents have been received.					
12) ☐ Acknowledgment is made of a claim for fore a) ☐ All b) ☐ Some * c) ☐ None of:	eign phority under 35 U.S.C. § 119	9(a)-(a) or (t).				
Priority under 35 U.S.C. § 119		D(=) (d) == (D				
·						
11) The oath or declaration is objected to by the						
Applicant may not request that any objection to Replacement drawing sheet(s) including the con						
10) The drawing(s) filed on is/are: a)						
9) The specification is objected to by the Exan						
Application Papers						
8) Claim(s) are subject to restriction ar	nd/or election requirement.					
7) Claim(s) is/are objected to.						
6) Claim(s) <u>7-39,41-57 and 60-65</u> is/are reject	ted.					
5) Claim(s) is/are allowed.						
4) Of the above claim(s) is/are with						
4) Claim(s) <u>37-39,41-57 and 60-65</u> is/are pen	ding in the application					
Disposition of Claims		•				
closed in accordance with the practice und		•				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
,—	This action is non-final.	•				
1) Responsive to communication(s) filed on 1	1 April 2005					
Any reply received by the Office later than three months after the mearned patent term adjustment. See 37 CFR 1.704(b). Status	nailing date of this communication, even if timely	filed, may reduce any				
THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFI after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, and if NO period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by statutory period for reply will period for repl	R 1.136(a). In no event, however, may a reply b reply within the statutory minimum of thirty (30) riod will apply and will expire SIX (6) MONTHS to atute, cause the application to become ABANDO	days will be considered timely. from the mailing date of this communication. ONED (35 U.S.C. § 133).				
A SHORTENED STATUTORY PERIOD FOR RE	EPLY IS SET TO EXPIRE 3 MONT	TH(S) FROM				
The MAILING DATE of this communication Period for Reply	appears on the cover sheet with th	ne correspondence address				
	Christopher R. Tate	1654				
Office Action Summary	Examiner	Art Unit				
	10/669,099	GORFINE, STEPHEN R.				
	Application No.	Applicant(s)				

Application/Control Number: 10/669,099

Art Unit: 1654

DETAILED ACTION

The amendment filed 11 April 2005 is acknowledged and has been entered. Claims 37-39, 41-57, and 60-65 have been examined on the merits. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Double Patenting

Claims 37-39, 41-57, and 60-65 (as amended) stand rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 21-26 of U.S. Patent No. 5,504,117 and over claims 7-20 of U.S. Patent No. 5,693,676 for the reasons set forth in the previous Office action (with respect to the instantly claimed method of ameliorating pain in a human associated with the selected anal disorders recited in the amended claims - as discussed below).

Although the conflicting claims are not identical, they are not patentably distinct from each other because the instantly claimed method and the claimed methods of US '117 and US '676 are each drawn to a method of ameliorating (controlling) pain associated with an anal disease/disorder - e.g., an anal fissure, anal ulcer, hemorrhoidal disease, and/or levator spasm via administering a composition comprising an effective amount of a nitric oxide donor (such as nitroglycerin or L-arginine) to the affected anal area/anal canal of a subject in need thereof. In addition, it would clearly have been obvious to one of ordinary skill in the art at the time the claimed invention was made to further include an art-recognized pain-relief agent such as a corticosteroid and/or local anesthetic within such a topical therapeutic composition for the well known benefits such an agent provides in terms of aiding in effectively providing pain relief to such a subject. Further, the instant claims encompass or are encompassed by the claimed methods of US '117 and '676.

Application/Control Number: 10/669,099

Art Unit: 1654

Applicants' response to the above obviousness-type double patenting rejections is that they be held in abeyance until some claims are deemed to be in condition for allowance at which time they intend to submit a suitable terminal disclaimer obviating these rejections. Accordingly, the ODP rejections stand until a suitable terminal disclaimer has actually been submitted.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher R. Tate whose telephone number is (571) 272-0970. The examiner can normally be reached on Mon-Thur, 6:30-4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on (571) 272-0974. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Page 4

Application/Control Number: 10/669,099

Art Unit: 1654

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Christopher R. Tate Primary Examiner Art Unit 1654